Humira/adalimumab litigation confirms Arrow declarations' availability

Litigation centred on the antibody adalimumab (marketed as Humira by AbbVie and indicated for psoriasis and some forms of arthritis) has confirmed the ability to obtain so-called Arrow declarations in the English courts.

24 July 2017

Actavis v Eli Lilly – Summary of Supreme Court Decision of 12 July 2017

The United Kingdom Supreme Court (UKSC) today handed down its judgment in the case of Actavis UK Limited and others v Eli Lilly and Company ([2017] UKSC 46) that has significantly changed the law of patent infringement in the UK.

12 July 2017

Full Federal Court Confirms an Application to list on the PBS Prior to Patent Expiry is a non infringing Act

Late last week, the Full Federal Court of Australia confirmed that the mere act of filing a Pharmaceutical Benefits Scheme (PBS) application for a generic pharmaceutical product is not, of itself, an act of infringement provided that the generic product will ...

19 April 2017

Brenzys lists on the Australian PBS and Pfizer denied discovery of documents to establish grounds for patent infringement

As of 1 April 2017, Samsung Bioepis' Brenzys, a biosimilar to Pfizer's Enbrel (active ingredient etanercept), will join the very short list of "a-flagged" biosimilars listed on the Australian Government's Pharmaceutical Benefits Scheme (PBS).

04 April 2017